SLC5A2 and diabetic kidney disease: GLP-1RAs have been approved for the management of hyperglycemia, prevention of atherosclerotic CV disease, and/or treatment of DKD patients at high risk for CV events, in spite of optimal therapy with metformin and SGLT2 inhibitors [161,162] (Figure 3).